FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients.

[1]  Luang Xu,et al.  High-throughput proteomic sample preparation using pressure cycling technology , 2022, Nature Protocols.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  Jinming Yu,et al.  ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation , 2021, Science advances.

[4]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.

[5]  R. Weichselbaum,et al.  The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation , 2021, Science Immunology.

[6]  Wanqing Chen,et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 , 2021, Chinese medical journal.

[7]  Yixuan Hou,et al.  FOSL2 promotes VEGF-independent angiogenesis by transcriptionnally activating Wnt5a in breast cancer-associated fibroblasts , 2021, Theranostics.

[8]  Chunhui Yuan,et al.  ProteomeExpert: a Docker image-based web server for exploring, modeling, visualizing and mining quantitative proteomic datasets , 2021, Bioinform..

[9]  Rui Hu,et al.  Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression , 2020, Aging.

[10]  C. Yuan,et al.  PulseDIA: Data-Independent Acquisition Mass Spectrometry using Multi-injection Pulsed Gas Phase Fractionation. , 2020, Journal of proteome research.

[11]  Lingling Wu,et al.  cGAS-STING–mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy , 2020, Science Translational Medicine.

[12]  Hong-Li Yan,et al.  Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1 , 2020, Journal of experimental & clinical cancer research : CR.

[13]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[14]  P. Zhou,et al.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer , 2020, Signal Transduction and Targeted Therapy.

[15]  A. Melcher,et al.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy , 2020, Nature Reviews Cancer.

[16]  Henry H. N. Lam,et al.  DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery , 2020, bioRxiv.

[17]  G. Kwapiszewska,et al.  Transcription factor Fra-2 and its emerging role in matrix deposition, proliferation and inflammation in chronic lung diseases. , 2019, Cellular signalling.

[18]  R. Weichselbaum,et al.  Tumor-reprogrammed resident T cells resist radiation to control tumors , 2019, Nature Communications.

[19]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[20]  E. Wagner,et al.  Fra-2-expressing macrophages promote lung fibrosis in mice. , 2019, The Journal of clinical investigation.

[21]  D. Jackson,et al.  Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.

[22]  J. Moan,et al.  High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer , 2019, BMC Cancer.

[23]  X. Fang,et al.  Fos‐like antigen 2 (FOSL2) promotes metastasis in colon cancer , 2018, Experimental cell research.

[24]  Zhen Zhang,et al.  Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  J. Parsons,et al.  Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. , 2018, Journal of proteomics.

[26]  E. Wherry,et al.  Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. , 2018, Cell reports.

[27]  F. Boisvert,et al.  The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature , 2018, Clinical Proteomics.

[28]  M. Weiser,et al.  AJCC 8th Edition: Colorectal Cancer , 2018, Annals of Surgical Oncology.

[29]  Elaine R. Mardis,et al.  Applications of Immunogenomics to Cancer , 2017, Cell.

[30]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[31]  Richard Emsley,et al.  Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. , 2016, The Lancet. Oncology.

[32]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[33]  Ludovic C. Gillet,et al.  Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps , 2015, Nature Medicine.

[34]  T. Beißbarth,et al.  Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Sunil Krishnan,et al.  Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Rosman,et al.  Complete Pathologic Response after Combined Modality Treatment for Rectal Cancer and Long-Term Survival: A Meta-Analysis , 2012, Annals of Surgical Oncology.

[37]  Geerard L Beets,et al.  Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[39]  H. Grabsch,et al.  Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer , 2010, Gut.

[40]  Karin Haustermans,et al.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.

[41]  V. Cerundolo,et al.  Aberrant Selection and Function of Invariant NKT Cells in the Absence of AP-1 Transcription Factor Fra-21 , 2009, The Journal of Immunology.

[42]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[43]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[44]  E. Wagner,et al.  Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1 , 2008, Proceedings of the National Academy of Sciences.

[45]  C. McConkey,et al.  Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[46]  B. Sander,et al.  CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma , 2007, Clinical Cancer Research.

[47]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[48]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[49]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[50]  H. Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.

[51]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[52]  G. Coukos,et al.  Radiotherapy combination opportunities leveraging immunity for the next oncology practice , 2017, CA: a cancer journal for clinicians.

[53]  Karin Haustermans,et al.  EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. , 2014, European journal of cancer.

[54]  Adjuvant therapy for patients with colon and rectum cancer. , 1990, Consensus statement. National Institutes of Health Consensus Development Conference.